Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate on pricing

This article was originally published in The Tan Sheet

Executive Summary

Colgate toothpaste price increases slated for mid-year will occur regardless of whether competitor Procter & Gamble follows suit with Crest, Colgate CEO Ian Cook says during a May 12 conference hosted by Goldman Sachs. Addressing analysts' concerns that other competitors will not raise prices, Cook notes the firm will stick to its plan, noting, "We feel the brand can support it, and the costs on the business suggest a need for it." He adds there are indications that "there is some price movement happening" with other brands. Colgate and P&G recently announced plans to increase product prices this year in order to offset higher commodity costs (1"The Tan Sheet" May 12, 2008, p. 7)...

You may also be interested in...



P&G, Colgate Hike Prices To Offset Rising Commodity Costs

Procter & Gamble and Colgate-Palmolive are among a number of major consumer products companies initiating price increases in order to offset rising commodity costs

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel